This contract is to advance the development of monovalent vaccines for prevention of marburg virus (marv) and sudan ebolavirus (sudv) disease.

Active Definitive Contract Awarded Last action

Contract number
75A50119C00055
Awardee
Awarding agency
Obligated
$145,378,689

Award facts

Opportunity
Contract value 98% obligated
  • $145,378,689.01 Current, with exercised options
  • $148,064,636.01 Potential, with all options
Completion date 88% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition after exclusion of sources · 3 offers Alternative Sources
Pricing
Cost No Fee
Place of performance
Washington, DC 20515, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00025 -$1,683,320
Supplemental Agreement for work within scope P00023 $0
Other Administrative Action P00022 $0
Supplemental Agreement for work within scope P00020 $2,500,000
Supplemental Agreement for work within scope P00019 $776,566
Supplemental Agreement for work within scope P00018 $0
Supplemental Agreement for work within scope P00017 $28,000,000
Supplemental Agreement for work within scope P00016 $0
Change Order P00015 $0
Funding Only Action P00014 $799,006
Funding Only Action P00013 $861,255
Supplemental Agreement for work within scope P00021 $0
Change Order P00012 $15,501,031
Supplemental Agreement for work within scope P00011 $0
Exercise an Option P00010 $21,829,011
Supplemental Agreement for work within scope P00009 $462,635
Other Administrative Action P00008 $0
Supplemental Agreement for work within scope P00007 $1,219,363
Change Order P00006 $0
Change Order P00005 $0
Exercise an Option P00004 · Advance the development of monovalent vaccines for prevention of marburg virus (marv) and sudan ebolavirus (sudv) disease. $34,506,940
Supplemental Agreement for work within scope P00003 · Update CO and NCE $0
Other Administrative Action P00002 · Admin MOD to change COR $0
Exercise an Option P00001 · Exercise options 1 and 2 $20,060,448
Original award $20,545,754
Show all 25

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a $148.1 million definitive contract to Albert B. Sabin Vaccine Institute, Inc. for advanced development of monovalent vaccines against Marburg virus and Sudan ebolavirus on September 26, 2019, under cost-no-fee pricing with an ultimate completion date of September 30, 2027.

The solicitation sought proposals for advanced research and development of medical countermeasures against biological threats, with Sabin selected to advance vaccine candidates toward FDA licensure. Place of performance is Washington, DC.

Service Contract Inventory reporting for FY2024 shows $16.6 million invoiced across 36.5 FTEs performing 76,140 contractor hours, yielding a derived government-paid rate of $217.76 per hour. Sabin subcontracted 83 percent of contractor hours across 22 subcontractors in that fiscal year.

Quick answers

Who was awarded contract 75A50119C00055?

75A50119C00055 was awarded to Albert B. Sabin Vaccine Institute, Inc. (The) by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 26, 2019.

How much is contract 75A50119C00055 worth?

The government has obligated $145,378,689 on 75A50119C00055. Its potential value, with all options, is $148,064,636.

Was contract 75A50119C00055 competed?

The extent of competition for 75A50119C00055 was full and open competition after exclusion of sources. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login